Literature DB >> 10370600

Reflections on three field lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction.

T Lerut1, W Coosemans, P De Leyn, G Deneffe, B Topal, C Van de Ven, D Van Raemdonck.   

Abstract

BACKGROUND/AIMS: One of the most controversial questions in the surgical treatment of carcinoma of the esophagus and gastroesophageal junction (GEJ) is the extent of lymph node dissection, in particular the value of the cervical lymph node dissection (the so-called third field).
METHODOLOGY: This study reflects a single institution's experience with this extensive lymphadenectomy, the technique of which is described in detail.
RESULTS: Adding the third field to the lymph node dissection markedly improved accuracy of staging. Unforeseen involvement of lymph nodes in the neck was found in 30%. In T3N+ tumors of the GEJ, as much as 16.6% of positive lymph nodes were detected in the neck. Locoregional recurrence without distant metastasis was found in 6 patients (17.8%) out of a group of 37 patients with a minimum follow-up of 5 years. All 6 patients had stage IV disease because of distant lymph node metastasis (M+Ly). In 3 of these patients, locoregional recurrence occurred only after 3 years or more. In a subsequent series of 100 esophagectomies performed between 1992 and July 1993 no difference in outcome between radical versus standard resection was noticed for early stage I and II. However, there is a tendency towards a better estimated 5-year survival in favor of radical dissections (21%) versus standard resection (12%) in stage III and IV.
CONCLUSIONS: Extensive three field lymphadenectomy can be safely performed without increasing hospital mortality (0%) and morbidity. Improved accuracy of staging, prolonged disease-free survival and potential increased cure rate are confirmed by our experience. Survival obtained with this technique has to be compared with survival obtained by other, multimodality treatment forms.

Entities:  

Mesh:

Year:  1999        PMID: 10370600

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  18 in total

Review 1.  Multimodality therapy for gastroesophageal cancers.

Authors:  Kenneth K Wang
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

2.  Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.

Authors:  Joerg Theisen; Bernd Krause; Christian Peschel; Roland Schmid; Hans Geinitz; Helmut Friess
Journal:  World J Gastrointest Surg       Date:  2009-11-30

Review 3.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

4.  Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers.

Authors:  G J S Jenkins; J Mikhail; A Alhamdani; T H Brown; S Caplin; J M Manson; R Bowden; N Toffazal; A P Griffiths; J M Parry; J N Baxter
Journal:  J Clin Pathol       Date:  2007-01-12       Impact factor: 3.411

5.  Isolated tumour cells in pathological node-negative lymph nodes adversely affect prognosis in cancer of the oesophagus or oesophagogastric junction.

Authors:  Martin J MacGuill; Ciara Barrett; Narayanasamy Ravi; George MacDonald; John V Reynolds
Journal:  J Clin Pathol       Date:  2007-01-12       Impact factor: 3.411

Review 6.  Current Status and Future Prospects for Esophageal Cancer Treatment.

Authors:  Makoto Sohda; Hiroyuki Kuwano
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-12-21       Impact factor: 1.520

Review 7.  The extent of lymphadenectomy in esophageal resection for cancer should be standardized.

Authors:  Eliza R C Hagens; Mark I van Berge Henegouwen; Miguel A Cuesta; Suzanne S Gisbertz
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

8.  Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus.

Authors:  Nasser Altorki; Michael Kent; Cathy Ferrara; Jeffrey Port
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

Review 9.  Lymph node dissection for esophageal cancer.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-03-26

10.  Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer.

Authors:  John Vincent Reynolds; Cian Muldoon; Donal Hollywood; Narayanasamy Ravi; Suzanne Rowley; Ken O'Byrne; John Kennedy; Thomas J Murphy
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.